Últimas noticias sobre Agilon Health (NYSE:AGL) Bolsa

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY REAL EST NEW by Agility Real Estate Inc.

Agility Real Estate Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

Deutsche Bank analyst Brian Bedell reiterates State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Hold and lowers the price target from $104 to $103.

News

Price Target

Reiteration

Analyst Ratings

Deutsche Bank Reiterates Hold on State Street, Lowers Price Target to $103

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) with a Buy and maintains $7 price target.

COCP

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $7 Price Target

Citigroup analyst Asiya Merchant maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $120 to $125.

Citigroup Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $125

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Buy and lowers the price target from $75 to $72.

Deutsche Bank Maintains Buy on H.B. Fuller, Lowers Price Target to $72

Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a Neutral and raises the price target from $142 to $152.

Citigroup Maintains Neutral on 3M, Raises Price Target to $152

Industry partners to provide funding and data to support ACAT&#x2122; model improvements
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT&#x2122;) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

Biotech

General

Simulations Plus And Enabling Technologies Consortium Announce Strategic Collaboration To Advance GastroPlus Enhancements

Global

P&G CFO Says Organic Sales In China Declined 3% In Q2

WIIM

ROKU

Roku shares are trading higher after Netflix reported strong quarterly earnings.

HC Wainwright &amp; Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) from Neutral to Neutral.

ATRA

HC Wainwright & Co. Reiterates Neutral on Atara Biotherapeuticsto Neutral

United Airlines shares are trading higher after the company reported better-than-expected Q4 financial results.

IBKR

Interactive Brokers shares are trading higher following better-than-expected Q4 financial results.

Citigroup analyst Christopher Allen maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Neutral and raises the price target from $80 to $85.

SCHW

Citigroup Maintains Neutral on Charles Schwab, Raises Price Target to $85

The Offering is expected to close on or about January 23, 2025, subject to the satisfaction of customary closing conditions.&nbsp;

MCTR

CTRL Group Prices $8M Initial Public Offering Of 2M Common Shares At $4/Share

RVSN

Rail Vision shares are trading higher after the company announced a binding MoU with Sujan Ventures to introduce its safety systems to the Indian railway market.

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Deutsche Bank analyst Steve Powers maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $80 to $78.

Deutsche Bank Maintains Hold on Estee Lauder Cos, Lowers Price Target to $78

Financing

IESC

IES Announced That It Has Amended And Restated Its Existing Credit And Security Agreement, Increasing The Commitment Amount Of The Revolving Credit Facility To $300M From $150M And Extending The Maturity Date To January 21, 2030 While Expanding The Size Of The Lending Group

Deutsche Bank analyst Steve Powers maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $184 to $178.

Deutsche Bank Maintains Buy on PepsiCo, Lowers Price Target to $178

Bernstein analyst Lance Wilkes initiated coverage of Agilon Health (AGL) with a Market Perform rating and $2.50 price target The company has enjoye...

Agilon Health initiated with a Market Perform at Bernstein

Macquarie initiated coverage of Agilon Health (AGL) with a Neutral rating and $3 price target Agilon health is a pioneer of value-based care with s...

Agilon Health initiated with a Neutral at Macquarie

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Netflix, MongoDB downgraded: Wall Street's top analyst calls

Worst performing stocks for tax loss selling – Wolfe

In a report released on January 8, Sean Dodge from RBC Capital maintained a Buy rating on Agilon Health (AGL – Research Report), with a price targe...

RBC Capital Reaffirms Their Buy Rating on Agilon Health (AGL)

Citi upgraded Agilon Health (AGL) to Neutral from Sell with a price target of $2.25, up from $1.75. The firm sees limited further downside to the s...

Agilon Health upgraded to Neutral from Sell at Citi

HIMS downgraded, agilon upgraded at Citi in 2025 Health Tech review

Stifel Nicolaus analyst Michael Craig Jones downgraded Agilon Health (AGL – Research Report) to a Hold on January 10 and set a price target of $2.0...

Agilon Health (AGL) was downgraded to a Hold Rating at Stifel Nicolaus

Bernstein analyst Lance Wilkes maintained a Hold rating on Agilon Health (AGL – Research Report) today and set a price target of $3.15. The company...

Bernstein Sticks to Their Hold Rating for Agilon Health (AGL)

Bernstein analyst Lance Wilkes raised the firm's price target on Agilon Health (AGL) to $3.15 from $2.50 on the back of higher MA rate, while keepi...

Agilon Health price target raised to $3.15 from $2.50 at Bernstein

ACHC

ACLS

AGCO

ALGM

AMKR

APLS

ASTH

ATKR

BIIB

BMRN

BRBR

CLVT

CNXC

COLD

DINO

DXCM

ENPH

FIVN

FLNC

HIMS

INTC

IONS

IPGP

LFST

MCHP

MRNA

MTCH

NEOG

NFLX

NTAP

OKTA

OPCH

PRVA

PTEN

QDEL

QRVO

REGN

REXR

SEDG

SGRY

STNE

SWKS

SYNA

WOLF

XRAY

Press Releases

agilon health to Participate at 2024 Wells Fargo Healthcare Conference

AGILON HEALTH INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of agilon health, inc. - AGL

AGILON HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of agilon health, inc. - AGL

agilon health Sets Date to Report Third Quarter 2024 Financial Results

Legal

AGILON ALERT: Bragar Eagel & Squire, P.C. is Investigating Agilon Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

agilon health to Participate at 2024 Wolfe Research Healthcare Conference

agilon health Reports Third Quarter 2024 Results

agilon health Reports ACO REACH Model Results for 2023 Performance Year

Agilon Health, Inc, B. Riley Financial, Target Corporation, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

GETY

RILY

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Agilon Health

Noticias

Últimas noticias sobre Agilon Health (NYSE:AGL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL